1

Identity

Glaxosmithkline, S.A.

A28228526

€956M

Amount awarded, solo awards 2016–2026

Amount awarded by year
YearAmountDistribution
2026*€286.4M
2025€211.3M
2024€216.3M
+ regional platforms
2023€83.2M
2022€87.9M
2021€40.4M
2020€14.4M
2019€8.6M
2018€2.6M
2017€3.5M
2016€1.1M
*2026: data to 31 October · 179 contracts in 2026 · Since 2024 this also includes data from regional platforms. · Solo awards, excluding JVs · Framework agreements at €0 · €M
1,026
Contracts (lots)
across 798 tenders
61
Buyers
70%
Single bidder
3
Awards in UTEs
not in the total

In figures

Volume

Between 2016 and 2026 it won 1,026 contracts worth €956M on its own, with 61 buyers. Its 3 joint-venture (UTE) contracts are shown separately.

Price

In 2024–2026 its median discount was 36.4%; the middle half of its discounts between 22.6% and 43.8% (26 comparable awards).

Competition

Since 2024, 29% of its comparable value was won with a discount and against other bidders. It was the only bidder in 70% of its contracts (2016–2026).

Renewals

89 contracts (€168M) come up for tender again in the next 24 months.

A UTE is a temporary joint venture: the contract is awarded to the UTE and each partner's share is not published. That is why these contracts are not added to Glaxosmithkline, S.A.'s total, and under «Show UTEs» the amounts are the full value of each contract (100%), not Glaxosmithkline, S.A.'s share.

Data up to 31 October 2026 · updated on 12 November 2026 · Source: official data, national and regional coverage

2

Its discounts

The discount at which it wins contested contracts, year by year.

2024–2026: median 36.4% · middle half between 22.6% and 43.8% · 26 awards

2017–2023: median 15.0% (13 awards) · 2024–2026: median 36.4% (26 awards).

2017–2026: median 29.7% · middle half between 14.6% and 38.5% · 39 awards

Discount on the tender budget, excluding VAT, on awards above the minor-contract threshold · Source: official data, national and regional coverage. Methodology →

Where it wins, and at what discount

In the report · these discounts, one by one

Each dot on the chart is an award. The report lists them all and groups them by buyer and by sector, next to the discounts of other companies with the same buyers.

By sector

Productos farmacéuticos

CPV 336

561 contracts · €713M

By buyer · 2024–2026

Departament de Salut

Productos farmacéuticos

40 contracts · €121M

Órgano de Contratación de la Ciudad Autónoma de Ceuta

Productos farmacéuticos

22 contracts · €912k

Request the report →

Full list: date, buyer, amount, budget, discount, bidders and a link to the official publication.

Distribution of its discounts
How far winning bids are below the published contract value — its contested awards, the same ones the chart shows.
Median discount: 36.4% below the published contract value · 26 awards (2024–2026).
Discount
Awards
5–15 %
4
15–30 %
5
30 %+
17

6 awards at the tender price, left out of the discounts.

3

How it wins

Whether it wins with or without competition.

Competition and pricing

46% of the comparable value since 2024 (€54.9M of €120M) was won at the tender price and without other bidders. €34.1M (29%) was awarded with a discount and against other bidders.

With a discount
26%
single bidder · 17 · €30.6M
29%
multiple bidders · 26 · €34.1M
At the tender price
46%
single bidder · 15 · €54.9M
0%
multiple bidders · 0

Comparable: 58 awards with a published budget and bidder count (€120M of €714M awarded since 2024). Percentages of value; the figure next to «bidders» is the number of awards. Source: official data, national and regional coverage.

Award procedure

Between 2016 and 2026, 61.1% of the value was awarded through negotiated without publicity procedure (40.8% of contracts); followed by Open (22.7%) and Other (10.7%).

Open · 22.7%
Negotiated without publicity · 61.1%
Other · 10.7%
Open
Simplified open
Based on a framework agreement
Negotiated without publicity
Other
4

Upcoming tenders and main buyers

When its contracts come back and who it sells to.

When its contracts come back

In the next 24 months 89 of its contracts come up for tender again, worth €168M.

Expected endBuyerValue
2026Servicio de Salud de las Illes Balears€1.25M
2026Gerencia de Servicio Sanitarios de Fuerteventura€170k
2026Gerencia de Servicio Sanitarios de Fuerteventura€75.5k
2026Gerencia de Servicio Sanitarios de Fuerteventura€6.17k
2026Gobierno Vasco-Dirección de Régimen Jurídico, Económico y Servicios Generales€9.53

and 84 more in the next 24 months · the report includes them all

Expected end year from the published duration (no extensions). The report includes the month and the discount it won each one at.

Who they sell to
BuyerContractsValue, €Period
Consejería de Sanidad (Comunidad de Madrid)15226 M2024–2026
Departament de Salut63191 M2020–2026
Servicio Andaluz de Salud11099 M2024–2026
Consejería de Sanidad de la Junta de Castilla y León3871 M2018–2026
Secretaría General de la Consejería de Sanidad de la Junta de Comunidades de Castilla-La Mancha4654 M2018–2026

and 56 more buyers

Sector activity
Top CPV codes — the EU classification system that identifies the type of works, services or supplies covered by each contract.

Between 2016 and 2026, 100.0% of the value it won on its own is in Medical & pharmaceuticals (CPV 33, 1,005 contracts).

Medical & pharmaceuticals
100.0%1005 contracts
Chemical products
0.0%1 contract
5

Recent awards

The evidence behind every insight in the report.

Latest 5 completed contracts (of 350)
Contracts whose expected completion date has passed.
DateContractBuyerBiddersValue
20/10/2026BAM Suministro hepatitis B lote 7 Centro Militar de Farmacia de la DefensaInspección General de Sanidad de la Defensa1€16.1k
09/06/2026rc_3º cbam_am_296_2024_glaxosmithkline, s.a.Servicio Andaluz de Salud1€241k
08/06/2026cpca 1º cbam glaxosmithkline, s.a. exp. 578/2025 suministro medicamentos exclusivos, cca: +6.i+e9q8…Servicio Andaluz de Salud1€383k
29/04/2026rc_2º cbam_am_296_2024_glaxosmithkline, s.a.Servicio Andaluz de Salud1€301k
27/04/2026LOTE 4 Vacuna frente a difteria, tétanos, tosferina acelular de contenido antígeno reducidoConsejería de Sanidad del Gobierno de Canarias2€168k
Full report on Glaxosmithkline, S.A.
Includes: its discount by buyer and sector · winning discounts by buyer and year · how it wins with each buyer · contract renewal calendar. The complete register of its awards in the last three full calendar years and the current year to date, in Excel.
€50 + VAT · VAT is calculated at payment according to your country. You will receive it in PDF and Excel by email within one working day. Every report is reviewed by a person before it is sent to you.
Order the report